Crossmark

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir

Crossref DOI link: https://doi.org/10.1186/s12879-019-3907-5

Published Online: 2019-03-25

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Laker, Eva Agnes Odongpiny https://orcid.org/0000-0002-7937-1538
Nabaggala, Maria Sarah

Kaimal, Arvind

Nalwanga, Damalie

Castelnuovo, Barbara

Musubire, Abdu

Kiragga, Agnes

Lamorde, Mohammed

Ratanshi, Rosalind Parkes-
Funding

Funding for this research was provided by:

Foundation for the National Institutes of Health (D43TW009771)
License Information

Text and Data Mining valid from 2019-03-25
More Information

Article History

Received: 27 February 2018

Accepted: 15 March 2019

First Online: 25 March 2019

Ethics approval and consent to participate

: All routinely collected clinic data is approved for analysis and reporting by the Makerere University Faculty of Medicine, Research and Ethics committee (approval number: 120–2009) and Uganda National Council for Science and Technology (approval number: 45683) hence the need for consent was waived by an IRB.

: Not applicable

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below